Search research articles
Contact Us
Filters
Showing results (181-190 of 216) with videos related to
Page
of 22
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 10, 2006
Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination
Michael Michael, Mick Thompson, Rod J Hicks, et al.
The Lancet. Gastroenterology & Hepatology
|
May 13, 2017
Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study
Brian G Czito, Dustin A Deming, Gayle S Jameson, et al.
Journal of Clinical Medicine
|
September 25, 2019
Consensus-Derived Quality Performance Indicators for Neuroendocrine Tumour Care
Braden Woodhouse, Sharon Pattison, Eva Segelov, et al.
BMC Cancer
|
December 17, 2022
Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group)
Fiona Day, Swetha Sridharan, James Lynam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 16, 2025
The Ave-Rec Trial: Phase II Trial of PDL1/PD1 Blockade with Avelumab after Chemoradiotherapy for Locally Advanced Resectable T3B-4/N1-2 Rectal Cancer
Michael Michael, Rachel Wong, Sanjeev Gill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 2, 2011
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib
Jochen K Lennerz, Eunice L Kwak, Allison Ackerman, et al.
Nature Medicine
|
March 1, 2024
A gut microbial signature for combination immune checkpoint blockade across cancer types
Ashray Gunjur, Yan Shao, Timothy Rozday, et al.
JAMA Oncology
|
October 3, 2024
Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic GEP-NENs
Jonathan M Loree, David Chan, Jennifer Lim, et al.
Annals of Surgical Oncology
|
March 25, 2017
TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG
Trevor Leong, B Mark Smithers, Karin Haustermans, et al.
Eclinicalmedicine
|
April 28, 2025
A methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney function
Geeta Sandhu, Evangeline Armstrong Gordon, Josephine Adattini, et al.
Page
of 22
Search research articles
Search
Showing results (181-190 of 216) with videos related to
Sort By:
Page
of 22
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 10, 2006
Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination
Michael Michael, Mick Thompson, Rod J Hicks, et al.
The Lancet. Gastroenterology & Hepatology
|
May 13, 2017
Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study
Brian G Czito, Dustin A Deming, Gayle S Jameson, et al.
Journal of Clinical Medicine
|
September 25, 2019
Consensus-Derived Quality Performance Indicators for Neuroendocrine Tumour Care
Braden Woodhouse, Sharon Pattison, Eva Segelov, et al.
BMC Cancer
|
December 17, 2022
Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group)
Fiona Day, Swetha Sridharan, James Lynam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 16, 2025
The Ave-Rec Trial: Phase II Trial of PDL1/PD1 Blockade with Avelumab after Chemoradiotherapy for Locally Advanced Resectable T3B-4/N1-2 Rectal Cancer
Michael Michael, Rachel Wong, Sanjeev Gill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 2, 2011
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib
Jochen K Lennerz, Eunice L Kwak, Allison Ackerman, et al.
Nature Medicine
|
March 1, 2024
A gut microbial signature for combination immune checkpoint blockade across cancer types
Ashray Gunjur, Yan Shao, Timothy Rozday, et al.
JAMA Oncology
|
October 3, 2024
Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic GEP-NENs
Jonathan M Loree, David Chan, Jennifer Lim, et al.
Annals of Surgical Oncology
|
March 25, 2017
TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG
Trevor Leong, B Mark Smithers, Karin Haustermans, et al.
Eclinicalmedicine
|
April 28, 2025
A methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney function
Geeta Sandhu, Evangeline Armstrong Gordon, Josephine Adattini, et al.
Page
of 22